Pharma and Healthcare Insight

Pharma & Healthcare Insight brings you analysis of regional trends, regulatory changes, projects and investments plus competitive intelligence on the growth strategies of leading companies in the sector

See Prices or Subscribe

Key stories from this month's issue...

Industry Trend Analysis - Significant Opportunities For Cardiovascular Diseases - JUNE 2017

Americas May 2017 / Latin America / Industry

Innovative medicines treating cardiovascular diseases will generate most of their revenue in developed markets. However, there is also significant demand for cheaper generic alternatives to cardiovascular therapeutics in emerging markets. Latin America represents a considerable growth opportunity given the high levels of obesity and raised blood cholesterol among the region's large and expanding population.


Industry Trend Analysis - Stroke Prevention Will Be Vital In Asia's Emerging Markets - JUNE 2017

Asia May 2017 / Asia / Industry

The burden of stroke is particularly serious in Asia, but acute treatment will be limited in the region's emerging markets. Focus will be on preventive actions, both primary and secondary, and this represents an opportunity for drugmakers.


Industry Trend Analysis - Varuby's EC Approval Will Further Amplify Interest In Tesaro - JUNE 2017

Emerging Europe May 2017 / Europe / Industry

This approval furthers Tesaro's position as a major player in the growing chemotherapy-induced nausea and vomiting drugs market, and marks the company's expansion into Europe. Blockbuster sales are ahead for Tesaro and the firm is a likely acquisition prospect.


Industry Trend Analysis - GCC Well-Placed To Attract Pharmaceutical Investment - JUNE 2017

Middle East & Africa May 2017 / Middle East / Industry

The Gulf Cooperation Council countries offer the most significant commercial opportunities for drugmakers. Despite suffering from a host of economic and political fragilities, the overall outlook is a favourable one, with the Gulf States favourably well-positioned within the wider Middle East and Africa region. Certainly, iIt is vital that pharmaceutical companies identify those markets with high growth potential as well as the levels of risk involved.


Industry Trend Analysis - Generic Competition To Continue To Hurt AstraZeneca Revenues - JUNE 2017

Western Europe May 2017 / United Kingdom / Industry

AstraZeneca's shareholders will keep a close eye on the company's management's strategy, the late-stage R&D pipeline and newly launched USD1.1bn cost-cutting plan. While investor focus on company activity has been strong since the decline in sales of the company's top blockbuster drugs - Nexium lost patent protection in the US in February 2015 and Crestor experienced patent expiry in the US in 2016 - the focus on company direction will be even stronger in 2017. AstraZeneca has faced a large shareholder rebellion over its pay arrangements for the company's chief executive and chief financial officer, with almost 40% of investors opposing the drugmaker's pay report for 2016.